Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (NASDAQ: KPTI) has announced equity grants to four newly-hired employees as of December 31, 2024. The grants include 101,250 stock options with an exercise price of $0.6763 per share and 108,540 restricted stock units (RSUs).

The stock options vest over four years, with 25% vesting after one year and 1/48th monthly thereafter. The RSUs vest over three years, with 33 1/3% vesting annually. Both grants require continued employment with Karyopharm. In case of a change in control event followed by termination for good reason or without cause within one year, all grants will immediately vest in full.

Insights

Legal & Compensation Analyst

This compensation package reveals strategic talent retention efforts amid challenging market conditions. The equity grants, valued at approximately $68,475 for stock options and $73,407 for RSUs at current share price, represent a modest but targeted investment in key personnel. The four-year vesting schedule for options and three-year schedule for RSUs align with industry standards for retention, while the change-in-control provisions offer protection that's particularly relevant given KPTI's low market capitalization of $85.3M.

The exercise price of $0.6763 reflects the company's current challenged stock position, trading well below historical levels. This pricing structure could provide significant upside potential for new hires if the company's commercialization efforts succeed, though it also indicates the risks facing the organization. The relatively small scale of these grants suggests targeted hiring rather than broad expansion, likely focusing on critical roles needed for ongoing operations.

NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 101,250 shares of Karyopharm's common stock and an aggregate of 108,540 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of December 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $0.6763 per share, the closing price of Karyopharm's common stock on the Grant Date, and vests over four years, with 25% of the total number of shares underlying the stock options vesting on the one-year anniversary of the employee's commencement date and 1/48th of the total number of shares vesting monthly thereafter, subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

In addition, each stock option and RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302341021.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What is the exercise price of KPTI stock options granted on December 31, 2024?

The stock options were granted with an exercise price of $0.6763 per share, which was Karyopharm's closing price on December 31, 2024.

How many shares were included in KPTI's December 2024 inducement grants?

The inducement grants included 101,250 stock options and 108,540 restricted stock units (RSUs).

What is the vesting schedule for KPTI's December 2024 RSU grants?

The RSUs vest over three years, with 33 1/3% of shares vesting on each of the three consecutive anniversaries of the grant date.

What happens to KPTI's inducement grants in case of a change in control?

The grants will fully vest if the employee is terminated for good reason or without cause within one year of a change in control event.